Tech Company Financing Transactions
Repare Therapeutics Funding Round
Versant Ventures, BDC Venture Capital and Celgene participated in a $68 million Series A funding round for Repare Therapeutics. The financing round was announced on 6/23/2017.
Transaction Overview
Company Name
Announced On
6/23/2017
Transaction Type
Venture Equity
Amount
$68,000,000
Round
Series A
Investors
Versant Ventures (Lead Investor) (Jerel Davis)
MPM Capital (Todd Foley)
Proceeds Purpose
With this financing, Repare emerges from Versant's Discovery Engines after an 18-month stealth period during which the company advanced its leading CRISPR-enabled synthetic lethality drug discovery platform, identified several promising oncology targets and moved multiple programs into preclinical development.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Bdwy. 15th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lloyd Segal
Chief Medical Officer
Maria Koehler
Chief Scientific Officer
Michael Zinda
Executive Vice President
Cameron Black
VP - Bus. Development
Kim Seth
Browse more venture capital transactions:
Prev: 6/23/2017: AproPLAN venture capital transaction
Next: 6/23/2017: Blockchain venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs